Goldman Sachs Group Inc. lessened its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 27.9% in the 4th quarter, HoldingsChannel reports. The fund owned 150,491 shares of the company’s stock after selling 58,275 shares during the period. Goldman Sachs Group Inc.’s holdings in Meridian Bioscience were worth $2,107,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of VIVO. Verity Asset Management Inc. bought a new position in shares of Meridian Bioscience during the 4th quarter worth approximately $161,000. Nisa Investment Advisors LLC raised its stake in shares of Meridian Bioscience by 90.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 13,020 shares of the company’s stock worth $182,000 after acquiring an additional 6,200 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Meridian Bioscience by 57.9% during the 4th quarter. Advisor Group Inc. now owns 13,446 shares of the company’s stock worth $188,000 after acquiring an additional 4,932 shares in the last quarter. Koch Industries Inc. bought a new position in shares of Meridian Bioscience during the 4th quarter worth approximately $202,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Meridian Bioscience during the 4th quarter worth approximately $202,000. Hedge funds and other institutional investors own 90.95% of the company’s stock.
Shares of Meridian Bioscience stock opened at $14.70 on Tuesday. The company has a current ratio of 5.82, a quick ratio of 3.96 and a debt-to-equity ratio of 0.28. Meridian Bioscience, Inc. has a 12-month low of $13.23 and a 12-month high of $16.45. The company has a market cap of $615.58, a price-to-earnings ratio of 21.97 and a beta of 0.96.
Several research analysts recently commented on the stock. Zacks Investment Research lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub upgraded shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th. Finally, Canaccord Genuity boosted their price objective on shares of Meridian Bioscience from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Friday, January 26th.
ILLEGAL ACTIVITY WARNING: “Meridian Bioscience, Inc. (VIVO) Position Lowered by Goldman Sachs Group Inc.” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/04/17/meridian-bioscience-inc-vivo-position-lowered-by-goldman-sachs-group-inc.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.